Redemption Date Announced for Warrants

Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA)

GlobeNewswireApr 15 09:20 ET

Cassava Sciences' Alzheimer's Treatment Shows Promise: A Strong Buy Recommendation

TipRanksMar 25 10:55 ET

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as

GlobeNewswireMar 25 09:13 ET

Express News | HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target

Moomoo 24/7Mar 5 06:43 ET

Cassava Sciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 447.46% HC Wainwright & Co. → $124 Reiterates Buy → Buy 08/08/2023 447.46% HC Wainwright & Co.

BenzingaMar 5 06:41 ET

Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral

GlobeNewswireMar 4 09:15 ET